Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMARKER-U01 Substudy 2
2020-001627-14Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mk-4830 and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Primary endpoint: Objective Response Rate (ORR). Started Jul 2020; status: active.
02
Drugs
mk-4830pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-001627-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001627-14.